AstraZeneca Proclaims Promising Long-Acting COVID-19 Antibody
Results For Evusheld Upgrade Due In H2 2023
Executive Summary
AstraZeneca vaccine chief Mark Esser is excited about the first in vitro data on AZD3152 which show that the antibody neutralizes all known variants, from Wuhan to Omicron XBB.1.5.
You may also be interested in...
NICE Confirms English Funding For Three COVID-19 Drugs, But Rejects Four Others
There is good news for medicines from Pfizer, GSK and Roche, but MSD, Gilead and AstraZeneca have all appealed against NICE’s decision not to recommend their products for treating COVID-19.
Anger Over Access To AstraZeneca's Evusheld Peaks In UK
News that the UK government will not procur any doses of AstraZeneca’s Evusheld for the prevention of COVID-19 infections in immunocompromised people has been greeted with dismay and the move will hurt the combo's already-limited sales growth.
Sanofi Moves Up In MS With Frexalimab Success
Much of the focus on the French major’s MS pipeline has been on the BTK inhibitor tolebrutinib but promising Phase II data on frexalimab have caught the eye.